IN2012DN02412A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02412A
IN2012DN02412A IN2412DEN2012A IN2012DN02412A IN 2012DN02412 A IN2012DN02412 A IN 2012DN02412A IN 2412DEN2012 A IN2412DEN2012 A IN 2412DEN2012A IN 2012DN02412 A IN2012DN02412 A IN 2012DN02412A
Authority
IN
India
Prior art keywords
therapeutic agent
dexanabinol
farnesyltransferase
cdk5
cdk2
Prior art date
Application number
Other languages
English (en)
Inventor
Malcolm Philip Young
Philip Mckeown
Original Assignee
Theraputics Plc E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraputics Plc E filed Critical Theraputics Plc E
Publication of IN2012DN02412A publication Critical patent/IN2012DN02412A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
IN2412DEN2012 2009-09-10 2010-09-10 IN2012DN02412A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0915877.5A GB0915877D0 (en) 2009-09-10 2009-09-10 Cancer cell apoptosis
PCT/GB2010/001710 WO2011030106A1 (en) 2009-09-10 2010-09-10 Cancer cell apoptosis

Publications (1)

Publication Number Publication Date
IN2012DN02412A true IN2012DN02412A (ja) 2015-08-21

Family

ID=41228122

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2412DEN2012 IN2012DN02412A (ja) 2009-09-10 2010-09-10

Country Status (18)

Country Link
US (2) US20120190735A1 (ja)
EP (1) EP2475364A1 (ja)
JP (2) JP5930204B2 (ja)
KR (1) KR20120090060A (ja)
CN (2) CN105935357A (ja)
AU (1) AU2010294055B2 (ja)
BR (1) BR112012005262A2 (ja)
CA (1) CA2771099A1 (ja)
GB (1) GB0915877D0 (ja)
IL (1) IL218008A (ja)
IN (1) IN2012DN02412A (ja)
MX (1) MX337433B (ja)
MY (1) MY161186A (ja)
NZ (1) NZ598652A (ja)
RU (1) RU2592230C2 (ja)
SG (1) SG178604A1 (ja)
WO (1) WO2011030106A1 (ja)
ZA (1) ZA201201981B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
GB0719771D0 (en) * 2007-10-10 2007-11-21 Therapeutics Ltd E Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma
GB0915877D0 (en) * 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
GB201207305D0 (en) * 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
CN116726181B (zh) * 2023-08-09 2023-10-20 四川省医学科学院·四川省人民医院 抑制nat9基因表达的试剂的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3249109A (en) 1963-11-01 1966-05-03 Maeth Harry Topical dressing
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4262003A (en) 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
IL80411A (en) 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
IL115245A (en) 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
EP1002535A1 (en) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
JP2004501145A (ja) 2000-06-22 2004-01-15 ファーモス コーポレイション 向精神作用をもたない新規なカンナビノイド
WO2003015713A2 (en) * 2001-08-20 2003-02-27 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes
CN100459982C (zh) * 2004-08-30 2009-02-11 鲁南制药集团股份有限公司 去氧氟尿苷的分散片剂型
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
GB0915877D0 (en) * 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis

Also Published As

Publication number Publication date
MY161186A (en) 2017-04-14
KR20120090060A (ko) 2012-08-16
MX337433B (es) 2016-03-04
WO2011030106A1 (en) 2011-03-17
SG178604A1 (en) 2012-04-27
JP5930204B2 (ja) 2016-06-08
CN105935357A (zh) 2016-09-14
EP2475364A1 (en) 2012-07-18
ZA201201981B (en) 2013-05-29
MX2012002992A (es) 2012-07-17
JP2013504550A (ja) 2013-02-07
BR112012005262A2 (pt) 2016-03-15
RU2012113875A (ru) 2013-10-20
IL218008A0 (en) 2012-04-30
US20120190735A1 (en) 2012-07-26
JP2015214579A (ja) 2015-12-03
IL218008A (en) 2016-10-31
NZ598652A (en) 2014-05-30
US20180042891A1 (en) 2018-02-15
RU2592230C2 (ru) 2016-07-20
AU2010294055A1 (en) 2012-04-05
CA2771099A1 (en) 2011-03-17
CN102573833A (zh) 2012-07-11
AU2010294055B2 (en) 2014-10-02
GB0915877D0 (en) 2009-10-14

Similar Documents

Publication Publication Date Title
IN2012DN02412A (ja)
CL2007001434A1 (es) Uso de un arn de interferencia de la enzima convertidora del factor de necrosis tumoral alfa (tace) para tratar enfermedades relacionadas con tnf alfa; y composicion que lo comprende.
CL2010001018A1 (es) Un cartucho transductor para ultrasonido conectado a un cuerpo para formar un cabezal para terapias.
UY31360A1 (es) Peptidos y polipeptidos permeabilizadores de celulas para celulas microbianas
CA3035532C (en) Psma-targeting compounds and uses thereof
TN2015000091A1 (en) Glucosylceramide synthase inhibitors
CO6640205A2 (es) Microorganismos y metodos para la biosintesis de p-toluato y tereftalato
MX2011006290A (es) Compuestos de aza-azuleno.
BRPI1004899B8 (pt) composto inibidor de fosfoinositida 3-quinase, composição farmacêutica e uso de um composto
BR112012010614A2 (pt) transdurtor curvado de ultrassom focalizado de alta intensidade (hifu)
GT201200271A (es) Proteínas que se unen al tnf-a
EP3049032A4 (en) Patient specific instrumentation (psi) for orthopedic surgery and systems and methods for using x-rays to produce same
EA201101520A1 (ru) Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
CL2008000496A1 (es) Compuestos derivados de purina; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades infecciosas, cancer, alergias y otras afecciones inflamatorias.
BRPI1010887A2 (pt) derivados de triazina e suas aplicações terapêuticas.
AR088512A1 (es) Anticuerpos dirigidos contra el tnf
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CR20120035A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona
BR112014029346A2 (pt) sistema e método implementado por computador para a montagem de um plano de tratamento médico
GT200800182A (es) Derivados de tetrahidronaftalina, procedimientos para prepararlos y su uso como antiinflamatorios
BR112012010616A2 (pt) transdutor de ultrassom focalizado de alta intensidade (hifu) curvado
BR112016008039A2 (pt) polipeptídeos do fator vii da coagulação
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
BR112014028443A8 (pt) Composição estéril esterilizada com radiação
ECSP13012613A (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol